Posaconazole as rescue therapy in African histoplasmosis

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 1, 2013, Pages 102-105

  Gonçalves, Daniel ^a   Ferraz, Catarina ^a   Vaz, Luisa ^a  

^a Universidade do Porto   (Portugal)

Author keywords

Histoplasmosis; Posaconazole; Salvage therapy

Indexed keywords

AMPHOTERICIN B; C REACTIVE PROTEIN; ITRACONAZOLE; POSACONAZOLE; TUBERCULOSTATIC AGENT;

ABDOMINAL MASS; AFRICA; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM DETECTION; CASE REPORT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTRIC SUCTION; HISTOPLASMOSIS; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; IMMUNE DEFICIENCY; LABORATORY TEST; LEUKOCYTOSIS; LYMPHADENOPATHY; LYMPHOMA; MALE; MEDICAL HISTORY; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHILIA; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; SCHOOL CHILD; SKIN FISTULA; SPUTUM CULTURE; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CHILD; HISTOPLASMOSIS; HUMANS; MALE; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 84873206667     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.06.027     Document Type: Article

References (15)

1. Wheat L.J. Histoplasmosis: a review from clinicians from non-endemic areas. Mycoses 2006, 49:274-282.
2. Manfredi R., Mazzoni A., Nanetti A., Chiodo F. Histoplasmosis capsulate and duboisii in Europe: the impact of the HIV pandemic, travel and immigration. Eur J Epidemiol 1994, 10:675-681.
3. Gugnani H.C., Muotoe-Okafor F. African histoplasmosis: a review. Rev Iberoam Micol 1997, 14:155-159.
4. Wheat L.J., Freifeld A.G., Kleiman M.B., et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807-825.
5. Krishna G., Sansone-Parsons A., Martinho M., et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007, 51:812-818.
6. Lehrnbecher T., Attarbaschi A., Duerken M., et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010, 29:1043-1045.
7. Loulergue P., Bastides F., Baudouin V., et al. Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis 2007, 13:1647-1652.
8. Global tuberculosis control - surveillance, planning, financing 2008, World Health Organization, World Health Organization, WHO/HTM/TB/2008.393.
9. Bjerregaard-Andersen M., da Silva Z.J., Ravn P., et al. Tuberculosis burden in an urban population: a cross sectional tuberculosis survey from Guinea Bissau. BMC Infect Dis 2010, 10:96.
10. Rakotoarivelo R.A., Razafimahefa S.H., Andrianiaina H.D., Randria M.J.D. Une histoplasmose africaine chez un patient malgache immunocompétent. Bull Soc Pathol Exot 2010, 103:19-21.
11. Restrepo A., Tobón A., Clark B., et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007, 54:319-327.
12. Connolly P., Wheat J., Schnizlein-Bick C., et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999, 43:322-328.
13. Kontoyiannis D.P. Invasive mycoses: strategies for effective management. Am J Med 2012, 125(1 Suppl.):S25-S38.
14. Nakamoto T., Hase I., Imaoka S., et al. Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin. Pharmacogenetics 2000, 10:571-575.
15. Cesaro S., Milano G.M., Aversa F. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis 2011, 30:595-596.